Safety Study of Bevacizumab (Avastin) With Thoracic Radiation in Non-small Cell Cell Lung Cancer

Inclusion criteria: 1. Cytologically or histologically confirmed stages II or III non-squamous NSCLC 2. No evidence of tumour invading major blood vessels and no active hemoptysis (bright red blood of at least ½ teaspoon) in the 28 days prior to randomization. 3. No prior systemic therapy for NSCLC. Prior surgery and/or extra-thoracic irradiation is permitted. 4. Presence of at least one measurable target lesion 5. Age 18 or greater. 6. WHO performance status of 0 or 1. 7. Acceptable pulmonary function as defined by a Fev1 of ≥30% and a DLCO of ≥40% of predicted 8. Life expectancy of at least 12 weeks. 9. Adequate hematological, renal and hepatic functions * Absolute neutrophil count \>2x109/l. * Platelet count \> 100x109/l. * Total bilirubin \< 1.5 x UNL * ASAT/ALAT \< 2 x UNL * Alkaline phosphatase \< 5 x UNL * Creatinine \< 130 μmol/L * Creatinine clearance \> 60 ml/min; measured or calculated 10. Urine dipstick for proteinuria \< 1+. If urine dipstick is ≥ 1, 24 hour urine must demonstrate \< 500 mg of protein in 24 hours. 11. No pre-existing sensory neurotoxicity grade 2 (CTC) 12. No active (uncontrolled) infection requiring antibiotics Exclusion criteria: 1. Mixed tumor types with small cell lung cancer or squamous cell carcinoma 2. Other serious diseases, such as heart failure, angina pectoris, myocardial infarction within the last 6 months, uncontrolled hypertension 3. Serious non-healing wound or ulcer. 4. ASAT and ALAT \> 1,5 x UNL 5. alkaline phosphatase 5 x UNL 6. Evidence of bleeding diathesis or coagulopathy. 7. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed with the patient before registration in the trial. 8. Participation in other trial with investigational drug or treatment modality.